

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 22834

Title: Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?

Reviewer's code: 00504156

Reviewer's country: Greece

Science editor: Jin-Xin Kong

Date sent for review: 2015-10-03 20:22

Date reviewed: 2015-10-12 02:31

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript is suitable for publication.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 22834

Title: Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?

Reviewer's code: 00506294

Reviewer's country: Spain

Science editor: Jin-Xin Kong

Date sent for review: 2015-10-03 20:22

Date reviewed: 2015-11-19 18:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

his article: "Metformin revisited: does this regulator of AMPK secondarily affect bone metabolism and prevent diabetic osteopathy?", is a good review about patients with long-term type 1 and type 2 diabetes mellitus that can develop skeletal complications as osteopenia, osteoporosis and an increased incidence of low-stress fractures; it is important to evaluate whether current antidiabetic treatments can secondarily affect bone metabolism. Many investigators have studied the effects of metformin on bone, and found data either in vitro, or in vivo and clinical evidence for an anabolic action of metformin on the skeleton. The authors discuss reports that have been unable to link metformin treatment with bone anabolic action. A consideration should be kept in mind when we evaluate metformin treatment for a patient with type 2 diabetes mellitus and metformin should probably not be considered an anti-osteoporotic drug but it have vascular benefits that can secondarily improve bone metabolism. We need new data for the evaluation of the effects of metformin on bone metabolism as a primary endpoint. The review is a complete analysis of this item and has interest for the readers of the Journal.